



SAFETY Meeting Minutes
IBC Committee
Zoom

MEETING TIME RECORDS

Meeting start time: 7/8/2026
3:00 PM
Meeting end time: 3:55 PM

VOTING MEMBER ATTENDANCE

Name of Regular/Alternate Member	Status (Member or Alternate)	Present by Teleconference?
Karl McKinstry	Member	Yes
Alvina Chu	Member	Yes
Melina Kinsey	Member	Yes
Kyle Rohde	Member	Yes
Stanley Haimes	Member	Absent
Hubert Salvail	Member	Yes
Judith Hecker	Member	Yes
Lane Coffee	Member	Absent
Yulia Gerasimova	Member	Yes
Teresa Krisch	Member	Yes

QUORUM INFORMATION

Number of SAFETY members on the roster: 10
Number required for quorum: 5

All members present by teleconference received all pertinent material before the meeting and were able to actively and equally participate in all discussions.

ATTENDANCE STATUS AND VOTING KEY

ABSTAIN:	Present for the vote, but not voting "For" or "Against."
ABSENT:	Absent for discussion and voting for reasons other than a conflicting interest.
RECUSED:	Absent from the meeting during discussion and voting because of a conflicting interest.
SUBSTITUTION:	When regular members and their alternate(s) are listed in the ATTENDANCE table above and an alternate member substitutes for the

	regular member this identifies the name of the alternate to indicate which individual is serving as the voting member for this vote. May be deleted if there are no substitutions.
--	--

GUEST NAMES

Previous Meeting minutes approved: June 2026 Meeting Minutes Approved

Motion: Karl McKinstry

Second: Hubert Salvail

REVIEW OF SUBMISSIONS

Initial Protocol

1. Review of SPROTO202600000028

Title:	Investigating the fine-tuning of stress response and virulence in Salmonella - Salvail
Investigator:	Hubert Salvail
Submission ID	SPROTO202600000028
Funding:	• Name: University of Central Florida, Grant Office ID: , Funding Source ID:
Agents:	• Bacillus subtilis • Escherichia coli K12 or derivative • Salmonella typhimurium • Other Cell Lines • Other Viruses
Agent Containment:	Biological Containment Levels: • Bacillus subtilis : BSL-1 • Salmonella typhimurium : BSL-2 • Escherichia coli K12 or derivative: BSL-1 • Escherichia coli K12 or derivative: BSL-1 • Other Cell Lines: BSL-1 • Other Viruses: BSL-1 • Other Viruses: BSL-1 • Other Viruses: BSL-1
Applicable NIH Guidelines:	• Section III-D-1-a • Section III-F-2 • Section III-F-3 • Section III-F-8-C-V • Section III-D-4 • Section III-F-7 • Section III-F • Section III-F-8-C-II • Section III-F-1 • Section III-D-1 • Section III-D • Section III-F-4 • Section III-F-8 • Section III-F-6

- a. **Description:** Non-typhoidal Salmonella (NTS) infections represent a major health burden, causing 93.8 millions cases of gastroenteritis, with 155,000 deaths, globally every year. The ability of Salmonella to cause disease largely depends on how it integrates environmental insults encountered both inside and outside the host and tightly regulates the expression of stress response and virulence genes in response to these cues. My research work aims at better understanding how Salmonella fine-tunes its stress response and virulence in order to cause disease.
- b. **Determination:** Modifications Required
Motion: Yulia Gerasimova
Second: Alvina Chu
- c. **Required modifications:**
1. Basic Information, Summary of Research – Please describe your methods in the summary
 2. Protocol Team Members – You are the only team member identified. Please add other team members if they will be working on the protocol.
 3. Recombinant or Synthetic Nucleic Acid Work Description – Please answer Question 3 & 4 the storage and usage locations.
 4. Bacteria, Yeast, Fungi, and Parasites - Agent, Escherichia coli K12 or derivative, Strain BW25113, Question #3 states that this agent will be used for “Mice infection.” However, Question #11 states that the agent is not used in animals. Please correct Question #11.
- d. **Votes:**
- | | |
|-------------------|--------------------|
| For: | 7 |
| Against: | 0 |
| Recused: | 1 (Hubert Salvail) |
| Absent: | 2 |
| Abstained: | 0 |

Initial Protocol**2. Review of SPROTO202600000027**

Title:	IBC protocol for Ex vivo Study - Rajaraman
Investigator:	Swaminathan Rajaraman
Submission ID	SPROTO202600000027
Funding:	• Name: University of Central Florida Research Foundation, Inc., Grant Office ID: , Funding Source ID:
Agents:	• Human Skin
Agent Containment:	Biological Containment Levels: • Human Skin: BSL-2
Applicable NIH Guidelines:	None

- a. **Description:** This study aims to evaluate the transdermal permeation of levothyroxine sodium delivered via a silk fibroin microneedle transdermal patch using an ex vivo Franz diffusion cell model. Certified, pathogen-screened human skin (Genoskin NativeSkin®), obtained from surgical donors with informed consent in full compliance with the Declaration of Helsinki, will be used as the biological membrane to closely simulate in vivo human skin conditions. Skin sections will be mounted between the donor and receptor compartments of Franz diffusion cells, and the transdermal patch will be applied to the stratum corneum surface of the donor compartment. Samples from the phosphate-buffered saline receptor fluid will be collected at predetermined time intervals and analyzed quantitatively to determine permeation kinetics and cumulative drug absorption over time
- b. **Determination:** Modifications Required
Motion: Melina Kinsey
Second: Karl McKinstry
- c. **Required modifications:**
1. Basic Information, Short title – Need a more descriptive short title
 2. Basic Information, Funding Sources – Need to list the funding source
- d. **Votes:**
- | | |
|-------------------|---|
| For: | 8 |
| Against: | 0 |
| Recused: | 0 |
| Absent: | 2 |
| Abstained: | 0 |

De Novo Review**3. Review of SPROTO202600000024**

Title:	Engineering cells and tissues of the musculoskeletal system - Kean
Investigator:	Thomas Kean
Submission ID	SPROTO202600000024
Funding:	• Name: The University of Central Florida Board of Trustees, Grant Office ID: , Funding Source ID:
Agents:	• Escherichia coli K12 or derivative • Skeletal Tissue • 293T • Other Primary Cells • Mesenchymal stromal cells • HUVEC • Chondrocytes • Lentivirus
Agent Containment:	Biological Containment Levels: • Escherichia coli K12 or derivative: BSL-1 • Escherichia coli K12 or derivative: BSL-1 • Escherichia coli K12 or derivative: BSL-1 • Mesenchymal stromal cells: BSL-2 • Other Primary Cells: BSL-2 • HUVEC: BSL-2 • 293T: BSL-2 • Chondrocytes: BSL-2 • Other Primary Cells: BSL-2 • Lentivirus: BSL-2 • Skeletal Tissue: BSL-2
Applicable NIH Guidelines:	• Section III-F-8-C-I • Section III-F • Section III-F-5 • Section III-F-8-C-VII

- a. **Description:** Use of human and animal cells to investigate cartilage, bone, tendon, muscle and diseases thereof. This research is primarily focused on cartilage and osteoarthritis. Current tissue culture methods produce cartilage that is deficient in mechanical properties; this is partly due to a lack of collagen, specifically collagen type II. Lentivirus containing the gaussia luciferase enzyme under extracellular matrix promoters will be used to transduce chondrocytes. These chondrocytes will then be used in chondrogenic culture and various growth factors and small molecules assessed for their ability to upregulate the expression of luciferase. Cells are expanded in culture, formatted into high-density cell aggregates, sheets, or bioprints

and studied for their ability to produce cartilage tissue while being treated with drugs, micronutrients or physical stimuli.

b. **Determination:** Modifications Required

Motion: Teresa Krisch

Second: Hubert Salvail

c. **Required modifications:**

1. Basic Information, Summary of Research – There is no mention/description of animal research, however under recombinant section animal work is mentioned.

2. Protocol Team Members – You are the only team member identified. Please add other team members if they will be working on the protocol.

3. Biosafety Summary - Select “Animals” and complete animal section

d. **Votes:**

For: 8

Against: 0

Recused: 0

Absent: 2

Abstained: 0

Initial Protocol

4. Review of SPROTO202600000023

Title:	NESTRE Intervention: A Multi-Biomarker Analysis of Burnout in Medical Students. - Schroeder
Investigator:	Kersten Schroeder
Submission ID	SPROTO202600000023
Funding:	• Name: TBD Customer, Grant Office ID: , Funding Source ID:
Agents:	• Human Derived Blood and Blood Types
Agent Characteristics:	Biological Agent Sources: • UCF COM Medical Student Participants (human subjects research)
Agent Containment:	Biological Containment Levels: • Human Derived Blood and Blood Types: BSL-2
Applicable NIH Guidelines:	None

- a. **Description:** The specific IRB protocol and number for blood samples to be collected is: STUDY00009170. Chronic occupational stress and burnout among medical

trainees are associated with significant neurobiological consequences, including the dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and a reduction in neurotrophic support. Neurofeedback, a non-invasive neuromodulation technique utilizes real-time electroencephalographic (EEG) monitoring and operant conditioning to train the brain toward more resilient physiological states. By providing participants with instantaneous feedback on neural activity, neurofeedback facilitates self-regulation and may mitigate the "allostatic load" caused by high-intensity academic environments. This study aims to investigate whether a 16-week neurofeedback intervention via the NESTRE platform can effectively modulate biomarkers of chronic stress and neuroplasticity specifically hair cortisol and Brain-Derived Neurotrophic Factor (BDNF) thereby providing a physiological basis for reducing burnout and enhancing cognitive longevity in medical student populations.

b. Determination: Modifications Required

Motion: Karl McKinstry

Second: Judy Hecker

c. Required modifications:

1. Protocol Team Members – Dr. Masternak is included as protocol personnel, In the summary clarify if his lab is being used to process samples. If samples are processed in his lab, add his lab room number to the agents under “Tissues, Blood or Body Fluids.”
2. Protocol Team Members - Ethan Bell is listed as not involved in procedures but is later listed as handling blood. Please mark him as “involved with procedures.”
3. Tissues, Blood, or Body Fluids, Human Derived Blood and Blood Types - Blood volumes are not consistent. For Question 3, “Describe the use of the agent,” mentioned that 5ml of blood will be collected while Question 7, “Quantity,” states 8ml. Please be consistent in the amount of blood collected.
4. Supporting Document – Please provide a transport SOP for the transport/shipping of samples from the Lake Nona campus to your lab on Main campus.

d. Votes:

For:	8
Against:	0
Recused:	0
Absent:	2
Abstained:	0

Amendment/CR**5. Review of SAMENDCR202600000008**

Title:	Amendment/CR for SPROTO202500000011 - Koszalinski
Investigator:	Rebecca Koszalinski
Submission ID	SAMENDCR202600000008
Funding:	None

a. Determination: Modifications Required**Motion:** Yulia Gerasimova**Second:** Judy Hecker**b. Required modifications:****1. Waste Management**

a) Question 3. Fill in the pertinent disinfectant information for the statements below:

“2) With appropriate PPE (lab coat, gloves, and eye protection), pour disinfectant (list disinfectant with appropriate dilution, Example: 1:10 freshly prepared bleach solution) onto the paper towels by working from the outside to the inside and let it sit for 20 minutes (If using bleach, the contact time is 20 minutes, for all others, consult manufacturer's directions on the label).”

“5) Flood the area with (name the disinfectant and dilution) working from the outside to the center of the spill for 20 minutes (contact time; 20 minutes for bleach)”

c. Votes:**For:** 8**Against:** 0**Recused:** 0**Absent:** 2**Abstained:** 0**REVIEW OF OTHER AGENDA ITEMS**

Melina Kinsey reported that there were no injuries or accidents.